And I think that’s what we’re going see with the heart and the lungs. Just because they’re out of the hospital doesn’t mean that there’s not long-term implications. “This is definitely a concern for all of these patients. “There is a lot of AKI that’s actually occurring well after hospitalization ,” Schlorff said. The SCD could one day be used outside of the ICU for hospitalized patients, potentially reducing the risk of long-term organ damage from COVID-19, for example. And obviously, chronic inflammation is a major concern for all of our long-term health.” “We don’t have to think about things as a heart issue or a kidney issue. “We potentially have a tool that can go across any of these different organs,” Schlorff said. SeaStar is focused on AKI for now, but Schlorff said the technology’s ability to reduce hyperinflammation means it will likely also fight acute respiratory distress syndrome in the lungs, myocarditis in the heart and other inflammatory conditions throughout the body. The SCD’s trick is mimicing the flow rate of the body’s capillary beds to which immune cells adhere, then calming the most highly activated cells before sending them back into the body. SeaStar Medical’s SCD treats a patient’s blood after it’s been filtered by a separate continuous renal replacement therapy device. So if you can turn that down, you allow that body to actually repair.” A steroid will turn the radio off, but you want to listen to the radio, so why not just turn the volume down? In our case, we’re turning the volume down in the most highly activated of these molecules or these effector cells that are causing all this damage. “We sequester them and turn the volume down. “We are able to collect the most highly activated immune cells,” he said. The SCD doesn’t filter out immune cells, but instead calms the most active damaging ones without affecting the reparative cells, Schlorff said. SeaStar’s device works as an add-on to continuous renal replacement therapy, which is 24-hour dialysis for ICU patients who can’t handle the faster flow rates of traditional hemodialysis. What we care about is how we can actually take that patient from a pro-inflammatory state to a reparative state.” We look at this as insult agnostic, so we don’t really care how it starts. “We are not going to reduce the front end, the pathogen or whatever it is. “We address the cytokine storm or hyperinflammation,” Schlorff said. The company used COVID-19 complications to demonstrate how safe and effective the SCD is in treating hyperinflamation across different organs regardless of the cause, whether it be viral, bacterial or from trauma or surgery. The treatment reduced mortality to 50% (compared to 81% in the control group), while patients who used the device for more than 96 hours saw an even lower mortality rate of 31%. SeaStar Medical CEO Eric Schlorff SeaStar most recently studied the use of its Selective Cytopheretic Device (SCD) on 22 COVID-19 patients with multiple organ failure in ICUs.
0 kommentar(er)
